We used a highly sensitive WST‐1 cell proliferation assay to assess the antiproliferative effect of BRAFi treatment following direct inhibition of IL‐6 and WNT5A signalling in HTB63‐R and A375‐R BRAFi‐R melanoma cell lines. The gene discussed is WNT5A; the disease is melanoma.